The Biotech ETF – IBB – Just Made New November Highs, What’s Next?
Investment experts and professional money managers almost always tell people to invest across a range of experts. This is usually in order to generate bigger returns in the long term. One of the sectors that is almost always favored by professionals is the biotech sector and the simple reason behind that is the fact that the sector has managed to grow at an impressive pace.
However, in order to pick stocks, an individual would need to conduct his own research with regard to different companies. Here is a look at three biotech stocks that should be tracked closely due to recent events.
PharmaCyte Biotech (PMCB)
PharmaCyte Biotech, Inc. (PharmaCyte) is a biotechnology company developing cellular therapies for cancer and diabetes based upon a proprietary cellulose-based live cell encapsulation technology known as “Cell-in-a-Box®.” This technology will be used as a platform upon which therapies for several types of cancer and diabetes are being developed.
What Happened This Week?
This week was important for the company as it hit a milestone never met. The company announced that its partner, Austrianova Singapore, has successfully completed the second and final GMP manufacturing run to produce PharmaCyte’s clinical trial product. The product is now ready for “release testing.”
The data from the “release testing” of both manufacturing runs will be included in an Investigational New Drug application (IND) and submitted to the U.S. Food and Drug Administration to support PharmaCyte’s planned clinical trial in patients with locally advanced, inoperable pancreatic cancer.
“We have cleared what was a major hurdle for us and have completed our most impactful milestone to date. Successfully completing two manufacturing runs is a milestone that has now been met as we progress toward our submission of an IND to the FDA so we can begin our clinical trial in LAPC.”PharmaCyte’s Chief Executive Officer, Kenneth L. Waggoner
NovaBay Pharmaceuticals (NBY)
The first biotech stock to consider is that of NovaBay Pharmaceuticals, Inc. (NYSE:NBY). The NovaBay stock has been on a tear this morning owing to an important product announcement from the company. The company issued a press release this morning in which it revealed that its product NovaSight has been launched on Amazon.
The product in question is a mineral supplement and a daily vitamin that is meant for the eyes. After the announcement was made, the stock rose by as much as 26.50% in Monday’s trade and it remains one of the stocks to watch on the market today. The announcement is a significant one and could have far-reaching implications for NovaBay.
BioCryst Pharmaceuticals (BCRX)
Another biotech stock that has been in the middle of a highly impressive rally in recent sessions is that of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX). The stock has gained over the course of the past three trading sessions and has generated gains of as much as 28% so far.
In a new development, the company completed a capital raise by offering its equity and managed to raise as much as $55 million. This prompted Bank of America analysts Tazeen Ahmad to upgrade the stock from neutral to buy. The capital raise and the upgrade possibly resulted in the remarkable rally in the BioCryst stock in recent days.
Disclaimer: Pursuant to an agreement between MIDAM VENTURES, LLC and Complete Investment And Management LLC, a Non-affiliate Third Party, Midam was hired for a period from 07/09/2019 – 8/09/2019 to publicly disseminate information about PharmaCyte Biotech including on the Website and other media including Facebook and Twitter. We were paid $150,000 (CASH) for & were paid “0” shares of restricted common shares. We were paid an additional $150,000 (CASH) BY Complete Investment And Management LLC, a Non-affiliate Third Party, AND HAVE EXTENDED coverage for a period from 8/12/2019 – 10/15/2019. We were paid an additional $150,000 (CASH) BY Complete Investment And Management LLC, a Non-affiliate Third Party, AND HAVE EXTENDED coverage for a period from 10/16/2019 – 11/15/2019.We may buy or sell additional shares of PharmaCyte Biotech in the open market at any time, including before, during or after the Website and Information, provide public dissemination of favorable Information. Click Here For Full Disclaimer.